抗细胞程序性死亡蛋白1配体1抗体(Anti-PDL1)检测试剂盒(酶联免疫吸附试验法)
ELISA Kit for Anti-Programmed Cell Death Protein 1 Ligand 1 Antibody (Anti-PDL1)
CD274; PDCD1LG1; B7-H; B7H1; PD-L1; PDCD1L1; PDCD1-LG1; Programed Death Ligand 1
产品包装(模拟)
产品包装(模拟)
实验结果图
标准曲线图
通过ISO 9001、ISO 13485质量体系认证
特异性
本试剂盒用于检测抗细胞程序性死亡蛋白1配体1抗体(Anti-PDL1)，经检测与其它相似物质无明显交叉反应。
由于受到技术及样本来源的限制，不可能完成对所有相关或相似物质交叉反应检测，因此本试剂盒有可能与未经检测的其它物质有交叉反应。
回收率
分别于定值血清及血浆样本中加入一定量的抗细胞程序性死亡蛋白1配体1抗体(Anti-PDL1)（加标样品），重复测定并计算其均值，回收率为测定值与理论值的比率。
| 样本 | 回收率范围(%) | 平均回收率(%) |
| serum(n=5) | 80-92 | 88 |
| EDTA plasma(n=5) | 91-104 | 101 |
| heparin plasma(n=5) | 86-101 | 96 |
精密度
精密度用样品测定值的变异系数CV表示。CV(%) = SD/mean×100
批内差：取同批次试剂盒对低、中、高值定值样本进行定量检测,每份样本连续测定20 次，分别计算不同浓度样本的平均值及SD值。
批间差：选取3个不同批次的试剂盒分别对低、中、高值定值样本进行定量测定，每个样本使用同一试剂盒重复测定8次，分别计算不同浓度样本的平均值及SD值。
批内差： CV<10%
批间差： CV<12%
线性
在定值血清及血浆样本内加入适量的抗细胞程序性死亡蛋白1配体1抗体(Anti-PDL1)，并倍比稀释成1:2，1:4，1:8，1:16的待测样本，线性范围即为稀释后样本中抗细胞程序性死亡蛋白1配体1抗体(Anti-PDL1)含量的测定值与理论值的比率。
| 样本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 90-98% | 80-94% | 78-96% | 82-89% |
| EDTA plasma(n=5) | 98-105% | 99-105% | 81-89% | 82-101% |
| heparin plasma(n=5) | 88-102% | 82-103% | 81-95% | 80-102% |
稳定性
经测定，试剂盒在有效期内按推荐温度保存，其活性降低率小于5%。
为减小外部因素对试剂盒破坏前后检测值的影响，实验室的环境条件需尽量保持一致，尤其是实验室内温度、湿度及温育条件。其次由同一实验员来进行操作可减少人为误差。
实验流程
1. 实验前标准品、试剂及样本的准备；
2. 加样（标准品及样本）100µL，37°C孵育1小时；
3. 吸弃，加检测溶液A100μL，37°C孵育1小时；
4. 洗板5次；
5. 加TMB底物90µL，37°C孵育10-20分钟；
6. 加终止液50µL，立即450nm读数。
实验原理
将抗原包被于96孔微孔板中，制成固相载体，向微孔中分别加入标准品或标本，其中的抗细胞程序性死亡蛋白1配体1抗体(Anti-PDL1)与连接于固相载体上的抗原结合，然后加入HRP标记的二抗，彻底洗涤后加入TMB底物显色。TMB在过氧化物酶的催化下转化成蓝色，并在酸的作用下转化成最终的黄色。颜色的深浅和样品中的抗细胞程序性死亡蛋白1配体1抗体(Anti-PDL1)呈正相关。用酶标仪在450nm波长下测定吸光度(O.D.值)，计算样品浓度。
相关产品
| 编号 | 适用物种：Mus musculus (Mouse，小鼠) | 应用(仅供研究使用，不用于临床诊断！) |
| RPA788Mu01 | 细胞程序性死亡蛋白1配体1(PDL1)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA788Mu02 | 细胞程序性死亡蛋白1配体1(PDL1)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA788Mu01 | 细胞程序性死亡蛋白1配体1(PDL1)多克隆抗体 | WB; IHC; ICC; IP. |
| PAA788Mu02 | 细胞程序性死亡蛋白1配体1(PDL1)多克隆抗体 | WB |
| SEA788Mu | 细胞程序性死亡蛋白1配体1(PDL1)检测试剂盒(酶联免疫吸附试验法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| AEA788Mu | 抗细胞程序性死亡蛋白1配体1抗体(Anti-PDL1)检测试剂盒(酶联免疫吸附试验法) | Enzyme-linked immunosorbent assay for Antibody Detection. |
| LMA788Mu | 细胞程序性死亡蛋白1配体1(PDL1)等多因子检测试剂盒(流式荧光发光法) | FLIA Kit for Antigen Detection. |
参考文献
| 杂志 | 参考文献 |
| Chinese Journal of Cancer | Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications[NCBI: PMC3937742] |
| Leukemia.? | High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial.[Pubmed:24732592] |
| Diabetes?Metab Res Rev. | PD‐L1 gene polymorphisms and low serum level of PD‐L1 protein are associated to type 1 diabetes in Chile[Pubmed:24816853] |
| Lancet Haematol | Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study[PubMed: 26686046] |
| Eur J Cancer. | High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis.[Pubmed:27039170] |
| Journal of Cancer Research and Clinical Oncology | Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer[article:10.1007] |
| Journal of Hematology & Oncology | PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma[pubmed:27737703] |
| Lung Cancer. | High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.[pubmed:28212990] |
| Oncotarget | Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predictssurvival in advanced biliary tract cancer patients treated with palliative chemotherapy.[pubmed:27780932] |
| Oncotarget | High post-treatment serum levels of soluble programmed cell death ligand 1 predict earlyrelapse and poor prognosis in extranodal NK/T cell lymphoma patients.[pubmed:27105512] |
| Oncotarget. | Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma[pubmed:27566569] |
| Cancer Immunol Immunother. | Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy.[pubmed:28349165] |
| Leukemia | Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients[leu2016385a] |
| Medicine | Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy.[pubmed:28207525] |
| Allergology International | Inverse correlation of soluble programmed cell death-1 ligand-1 (sPD-L1) with eosinophil count and clinical severity in allergic rhinitis patients[pubmed:27617656] |
| Medicine | Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy[PMC5319514] |
| American Journal of Respiratory and Critical Care Medicine | Soluble Programed Death Receptor 1 Ligand (sPD-L1) in Pleural Fluid of Patients with Malignant Pleural Mesothelioma (MPM)[Pdf:10.1164] |
| Clinical Lung Cancer | Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer[Pubmed:29859759] |
| Journal of Rheumatology | Increased levels of soluble programmed death ligand 1 associate with malignancy in patients with dermatomyositis[Pubmed:29419471] |
| Translational Oncology | High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma[Pubmed:29698935] |
| Immunology Letters | Increased levels of soluble co-stimulatory molecule PD-L1 (B7-H1) in the plasma of viraemic HIV-1+ individuals[Pubmed: 30236481] |
| Journal of Cancer Research and Clinical Oncology | Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma[Pubmed: 30267213] |
| Annals of Surgical Oncology | Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between …[Pubmed: 30565045] |
| American Journal of Reproductive Immunology | Identification of programmed cell death 1 and its ligand in the testicular tissue of mice[Pubmed: 30578744] |
| PLoS One | Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated …[Pubmed: 30807610] |
| Endocrine Connections | Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer[Pubmed: 31252406] |
| Scientific Reports | Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer[Pubmed: 31366979] |
| Critical Reviews in Oncology / Hematology | The Clinical Significance of Soluble PD-1 and PD-L1 in Lung Cancer[Pubmed: 31675543] |
| PLoS One | Clinical implications of APOBEC3A and 3B expression in patients with breast cancer[Pubmed: 32176735] |
| Cancers | Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study[Pubmed: 32085544] |
| Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma[Pubmed: 32054467] | |
| LIVER INTERNATIONAL | The prognostic role of soluble transforming growth factor‐β and its correlation with soluble programmed death‐ligand 1 in biliary tract cancer[Pubmed: 32780918] |
| CANCER IMMUNOLOGY IMMUNOTHERAPY | Prognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colorectal cancer patients[Pubmed: 32577816] |
| Soluble PD-L1: a potential immune marker for HIV-1 infection and virological failure[Pubmed: 32443313] | |
| Cancer Immunol Immunother | The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte[33688997] |
| Acta Biochim Biophys Sin | Prognostic prospect of soluble programmed cell death ligand-1 (sPD-L1) in cancer management[34180502] |
| EMBO J | Microglial PD‐1 stimulation by astrocytic PD‐L1 suppresses neuroinflammation and Alzheimer's disease pathology[34825707] |
| Mol Pharm | A Novel Small Cyclic Peptide-Based 68Ga-Radiotracer for Positron Emission Tomography Imaging of PD-L1 Expression in Tumors[34910492] |
| Mol Hum Reprod | Macrophage Associated Immune Checkpoint CD47 Blocking Ameliorates Endometriosis[Pubmed:35404426] |
| Journal of Nanobiotechnology | Microbial hydrogen “manufactory” for enhanced gas therapy and self-activated immunotherapy via reduced immune escape[Pubmed:35705974] |
| Medicina | Assessment of the RANTES Level Correlation and Selected Inflammatory and Pro-Angiogenic Molecules Evaluation of Their Influence on CRC Clinical Features: A …[Pubmed:35208526] |
